Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: A prospective randomized controlled study

Teruhiko Yokoyama, Katsutoshi Uematsu, Toyohiko Watanabe, Katsumi Sasaki, Hiromi Kumon, Atsushi Nagai

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective. To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (1-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB). Material and methods. Men aged at least 50 years who had a total International Prostate Symptom Score (IPSS) of 8 or higher and bladder dairy documenting micturition frequency (more than eight micturitions/24 h) and urgency (more than one episode/24 h), with or without urgency urinary incontinence were randomized into three groups: group N, naftopidil (50 mg once daily) only; group P, propiverine hydrochloride (20 mg once daily); and group NP, naftopidil (50 mg once daily) plus propiverine hydrochloride (20 mg once daily) for a 4-week treatment regimen. Results. A total of 66 men, including 20 in group N, 23 in group P and 23 in group NP, were treated and 58 (87.9%) completed the 4 weeks of treatment. IPSS improved significantly in groups N and NP. Urinary frequency improved significantly in groups P and NP. Postvoid residual urine volume increased significantly in groups P and NP. Significant improvements in urgency episodes were noted in each group. One patient in group P required catheterization owing to acute urinary retention and another stopped medication because of difficulty in voiding. Conclusion. These results suggest that each treatment showed effectiveness for male LUTS with OAB. However, there are some possibilities of adverse effects with propiverine hydrochloride monotherapy.

Original languageEnglish
Pages (from-to)307-314
Number of pages8
JournalScandinavian Journal of Urology and Nephrology
Volume43
Issue number4
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Overactive Urinary Bladder
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Urination
Prostate
Pyridinolcarbamate
Muscarinic Antagonists
Residual Volume
Urinary Retention
Urinary Incontinence
Therapeutics
Catheterization
Adrenergic Receptors
Urinary Bladder
Urine
Safety
naftopidil
propiverine

Keywords

  • 1-Adrenoceptor antagonist
  • Antimuscarinics
  • Benign prostatic hyperplasia
  • Lower urinary tract symptoms
  • Naftopidil
  • Overactive bladder
  • Propiverine

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

@article{726829780a764767af89ad9c2e0ca660,
title = "Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: A prospective randomized controlled study",
abstract = "Objective. To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (1-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB). Material and methods. Men aged at least 50 years who had a total International Prostate Symptom Score (IPSS) of 8 or higher and bladder dairy documenting micturition frequency (more than eight micturitions/24 h) and urgency (more than one episode/24 h), with or without urgency urinary incontinence were randomized into three groups: group N, naftopidil (50 mg once daily) only; group P, propiverine hydrochloride (20 mg once daily); and group NP, naftopidil (50 mg once daily) plus propiverine hydrochloride (20 mg once daily) for a 4-week treatment regimen. Results. A total of 66 men, including 20 in group N, 23 in group P and 23 in group NP, were treated and 58 (87.9{\%}) completed the 4 weeks of treatment. IPSS improved significantly in groups N and NP. Urinary frequency improved significantly in groups P and NP. Postvoid residual urine volume increased significantly in groups P and NP. Significant improvements in urgency episodes were noted in each group. One patient in group P required catheterization owing to acute urinary retention and another stopped medication because of difficulty in voiding. Conclusion. These results suggest that each treatment showed effectiveness for male LUTS with OAB. However, there are some possibilities of adverse effects with propiverine hydrochloride monotherapy.",
keywords = "1-Adrenoceptor antagonist, Antimuscarinics, Benign prostatic hyperplasia, Lower urinary tract symptoms, Naftopidil, Overactive bladder, Propiverine",
author = "Teruhiko Yokoyama and Katsutoshi Uematsu and Toyohiko Watanabe and Katsumi Sasaki and Hiromi Kumon and Atsushi Nagai",
year = "2009",
month = "9",
doi = "10.1080/00365590902836740",
language = "English",
volume = "43",
pages = "307--314",
journal = "Scandinavian Journal of Urology",
issn = "2168-1805",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder

T2 - A prospective randomized controlled study

AU - Yokoyama, Teruhiko

AU - Uematsu, Katsutoshi

AU - Watanabe, Toyohiko

AU - Sasaki, Katsumi

AU - Kumon, Hiromi

AU - Nagai, Atsushi

PY - 2009/9

Y1 - 2009/9

N2 - Objective. To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (1-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB). Material and methods. Men aged at least 50 years who had a total International Prostate Symptom Score (IPSS) of 8 or higher and bladder dairy documenting micturition frequency (more than eight micturitions/24 h) and urgency (more than one episode/24 h), with or without urgency urinary incontinence were randomized into three groups: group N, naftopidil (50 mg once daily) only; group P, propiverine hydrochloride (20 mg once daily); and group NP, naftopidil (50 mg once daily) plus propiverine hydrochloride (20 mg once daily) for a 4-week treatment regimen. Results. A total of 66 men, including 20 in group N, 23 in group P and 23 in group NP, were treated and 58 (87.9%) completed the 4 weeks of treatment. IPSS improved significantly in groups N and NP. Urinary frequency improved significantly in groups P and NP. Postvoid residual urine volume increased significantly in groups P and NP. Significant improvements in urgency episodes were noted in each group. One patient in group P required catheterization owing to acute urinary retention and another stopped medication because of difficulty in voiding. Conclusion. These results suggest that each treatment showed effectiveness for male LUTS with OAB. However, there are some possibilities of adverse effects with propiverine hydrochloride monotherapy.

AB - Objective. To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (1-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB). Material and methods. Men aged at least 50 years who had a total International Prostate Symptom Score (IPSS) of 8 or higher and bladder dairy documenting micturition frequency (more than eight micturitions/24 h) and urgency (more than one episode/24 h), with or without urgency urinary incontinence were randomized into three groups: group N, naftopidil (50 mg once daily) only; group P, propiverine hydrochloride (20 mg once daily); and group NP, naftopidil (50 mg once daily) plus propiverine hydrochloride (20 mg once daily) for a 4-week treatment regimen. Results. A total of 66 men, including 20 in group N, 23 in group P and 23 in group NP, were treated and 58 (87.9%) completed the 4 weeks of treatment. IPSS improved significantly in groups N and NP. Urinary frequency improved significantly in groups P and NP. Postvoid residual urine volume increased significantly in groups P and NP. Significant improvements in urgency episodes were noted in each group. One patient in group P required catheterization owing to acute urinary retention and another stopped medication because of difficulty in voiding. Conclusion. These results suggest that each treatment showed effectiveness for male LUTS with OAB. However, there are some possibilities of adverse effects with propiverine hydrochloride monotherapy.

KW - 1-Adrenoceptor antagonist

KW - Antimuscarinics

KW - Benign prostatic hyperplasia

KW - Lower urinary tract symptoms

KW - Naftopidil

KW - Overactive bladder

KW - Propiverine

UR - http://www.scopus.com/inward/record.url?scp=70249116115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249116115&partnerID=8YFLogxK

U2 - 10.1080/00365590902836740

DO - 10.1080/00365590902836740

M3 - Article

C2 - 19396723

AN - SCOPUS:70249116115

VL - 43

SP - 307

EP - 314

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

SN - 2168-1805

IS - 4

ER -